Study of Nivolumab in Subjects With Classical Hodgkin's Lymphoma (Registrational) (CheckMate 205)

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B & C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma subjects.


Study Type: Interventional
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects
Estimated Enrollment: 294
Study Start Date: July 2014
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)

Arms:
- Experimental: Nivolumab (Cohort A, B, C and D)